Table 7.
Clinical symptoms and laboratory findings of severe COVID-19 patients before and after treatment with Nanocurcumin and placebo.
| Severe COVID-19 patients |
Placebo group |
|||||
|---|---|---|---|---|---|---|
| Before treatment (n = 20) | After treatment (n = 19) | P value | Before treatment (n = 20) | After treatment (n = 15) | P value | |
| Fever (N, %) | <0.0001 | ns | ||||
| <37.3 °C | 11 (55%) | 4 (20%) | 9 (45%) | 8 (53%) | ||
| 37.3–38.0 °C | 5 (25%) | 2 (10%) | 6 (30%) | 5(33%) | ||
| 38.1–39.0 °C | 3 (15%) | 0 (0%) | 2 (10%) | 1 (6.6%) | ||
| >39.0 °C | 1 (5%) | 0 (0%) | 3 (15%) | 1 (6.6%) | ||
| Cough (%) | 15 (75%) | 2 (10%) | <0.0001 | 11 (55%) | 7 (47%) | ns |
| Dyspnea (%) | 7 (35%) | 1 (5%) | <0.0001 | 9 (45%) | 2 (15%) | 0.03 |
| C-reactive protein ≥10 mg/L (%) | 17 (85%) | 5 (26%) | <0.0001 | 14 (70%) | 9 (60%) | ns |
| Lactate dehydrogenase, U/L | <0.0001 | 0.02 | ||||
| ≤245 (%) | 11 (55%) | 16 (84%) | 9 (45%) | 12 (80%) | ||
| >245 (%) | 8 (40%) | 3 (15%) | 11 (55%) | 3 (20%) | ||
| Creatinine, μmol/L | <0.0001 | ns | ||||
| ≤133 (%) | 16 (80%) | 8 (42%) | 17 (85%) | 13 (86%) | ||
| >133 (%) | 4 (20%) | 11 (57%) | 3 (20%) | 2 (13%) | ||
| White blood cell count | <0.0001 | ns | ||||
| ×109/L | 6 (25%) | 5 (26%) | 8 (40%) | 5 (33%) | ||
| <4 (%) | 10 (55%) | 9 (47%) | 9 (45%) | 6 (40%) | ||
| 4–10 (%) | 4 (20%) | 5 (26%) | 3 (15%) | 4 (26%) | ||
| >10 (%) | ||||||
| Lymphocyte count ×109/L | <0.0001 | ns | ||||
| <1·0 (%) | 15 (75%) | 10 (52%) | 14 (70%) | 8 (53%) | ||
| ≥1·0 (%) | 5 (25%) | 9 (47%) | 6 (30%) | 7 (46%) | ||
| Platelet count | <0.0001 | 0.04 | ||||
| <100 (%) | 11 (55%) | 5 (26%) | 13 (65%) | 4 (26%) | ||
| ≥100 (%) | 9 (45%) | 14 (73%) | 7 (35%) | 11 (73%) | ||
| Bilateral involvement of chest radiographs | 16 (80%) | 9 (47%) | <0.0001 | 18 (90%) | 6 (40%) | 0.001 |
| Mechanical ventilation | 2 (10%) | 0 (0%) | ns | 1 (5%) | 0 (0%) | ns |